Info on SGNC
Sanguine Corporation Ticker: SGNC Page 1 of 10
Complete Financials: March 1998 Exchange OTC
FY END DEC
ISSUE DATA (06/12/98) PER SHARE DATA RATIOS
Price $ 1.09 EPS (TTM) $ -0.01 P/E (TTM) NM
52W High $ 1.16 Div. Rate $ NA Yield 0.00 %
52W Low $ 0.19 Book Value $ -0.03 Price/Book NM
Shrs Out 21.01 Mil Cash $ NM ROE (TTM) NM %
Float 7.80 Mil Rev (TTM) $ NA ROA (TTM) -1,800.00 %
Mon. Vol 0.00 Mil Curr. Ratio NM
Beta NA LT Dbt/Eqty NM
BRIEF: Sanguine Corporation, a development stage company,
is engaged in the development of a synthetic red blood cell
product called PHER-02, a second generation version of
Fluosol, the only FDA-approved synthetic blood product to
date. For the 3 months ended 3/31/98, the Company reported
no revenues. Net loss fell 38% to $37K. Lower loss
reflects lower research and development expenses and the
absence of $12K in consultant fees.
Sanguine Corporation QUARTERLY SUMMARY Page 2 of 10
HISTORICAL QUARTERLY RESULTS(Thousands of U.S. Dollars)
REVENUE 1995 1996 1997 1998
1st Qtr MAR 0 0 0 0
2nd Qtr JUN 0 0 0
3rd Qtr SEP 0 0 0
4th Qtr DEC 0 0 0
EPS (U.S. Dollars per share)
1st Qtr MAR -0.003 -0.003 -0.003 -0.002
2nd Qtr JUN -0.002 -0.003 -0.001
3rd Qtr SEP -0.003 -0.002 -0.002
4th Qtr DEC -0.012 -0.002 -0.003
FY'95, 2,841,000 shares issd., & FY'96 1,315,864 shares
issd. for services rendered and for satisfaction of certain
liabilities.
DIVIDENDS EMPLOYEES
Last Dividend Decl. $ NA # Employees 2
Last Div Ex-Date NA Sales/Employee (TTM) NM
Last Div Pay Date NA Net. Income/Empl.(TTM) NM
Sanguine Corporation COMPANY COMPARISON Page 3 of 10
TO THE BIOTECHNOLOGY AND S&P 500 AGGREGATES
VALUATION RATIOS: COMPANY INDUSTRY S&P 500
P/E Ratio NM 38.46 29.25
Dividend Yield 0.00 0.01 1.44
Price to Tangible Book -43.76 7.63 9.97
Price to Book NM 7.02 7.01
Price to Free Cash Flow -547.00 46.29 42.47
GROWTH STATISTICS:
3 Yr Rev Growth NM 28.60 14.50
3 Yr EPS Growth NM 24.74 15.67
3 Yr Div Growth NM 10.53 10.88
Reinvestment Rate 100.00 99.77 67.35
PROFITABILITY RATIOS:
Net Profit Margin NM 11.44 10.41
Return on Equity NM 1.42 21.90
Interest Coverage -11.00 -8.84 10.16
FINANCIAL STRENGTH RATIOS:
Current Ratio NM 5.42 1.46
LT Debt to Equity NM 0.34 0.79
Total Debt to Equity NM 0.39 1.05
Sanguine Corporation EQUITY, OFFICERS & ADDRESS Page 5 of 10
Common Stock $.001 Par, 5/98, 100M auth., 21,010,004 issd.
Insiders control approx. 63%. Public Offering 6/74, 3M
shares @ $.02. IPO - N/A: 14,589,775 shares issd. 6/93 in
acquisition of Sanguine Corporation (California). (As of
12/97) STD: $15K @ 10%, $89K @ 12%.
OFFICERS: Thomas C. Drees Ph.D., Chmn./Pres./CEO, David E.
Nelson, CFO, Anthony G. Hargreaves, VP/Secy./Treas.
TRANSFER AGENT: Continental Stock Transfer & Trust.
Company reincorporated 1992 in NV. Direct inquiries to:
David E. Nelson, CFO.
ADDRESS & PHONE NUMBERS
Sanguine Corporation
101 East Green Street, #11
Pasadena, CA 91105
PHONE: (626) 405-0079
Sanguine Corporation ANNUAL INCOME STATEMENT Page 6 of 10
(Thousands of U.S. Dollars)
12M 12/31/94 12M 12/31/95 12M 12/31/96 12M 12/31/97
Total Revenue 0 0 0 0
Depreciation 1 1 1 1
Research/Development 138 101 93 79
Med./Off./Auto/Legal 53 56 41 37
Interest Expense 5 6 7 10
Travel/Stock/Consul. 3 180 48 20
Salaries/Wages 8 18 18 18
Taxes/Promotions 23 5 3 1
Total Expenses 231 367 211 166
Operating Income -231 -367 -211 -166
Sanguine Corporation ANNUAL INCOME STATEMENT Page 7 of 10
(Thousands of U.S. Dollars)
12M 12/31/94 12M 12/31/95 12M 12/31/96 12M 12/31/97
Operating Income -231 -367 -211 -166
Income Before Taxes -231 -367 -211 -166
Income Taxes 0 0 0 0
Income After Taxes -231 -367 -211 -166
Pri/Bas EPS Ex. XOrd -0.014 -0.021 -0.011 -0.008
Pri/Bas EPS In. XOrd -0.014 -0.021 -0.011 -0.008
Primary/Basic Avg Sh 16,587.13 17,396.97 19,946.77 20,877.72
Common Dividends/Shr 0.0000 0.0000 0.0000 0.0000
Sanguine Corporation SELECTED INCOME STATEMENT Page 8 of 10
(Thousands of U.S. Dollars)
QUARTERS YEAR TO DATE
3M 03/31/97 3M 03/31/98 3M 03/31/97 3M 03/31/98
Revenue 0 0 0 0
Operating Expenses 59 37 59 37
Operating Income -59 -37 -59 -37
Non-Operating Income 0 0 0 0
Non-Operating Expenses 0 0 0 0
Income Before Taxes -59 -37 -59 -37
Income Taxes 0 0 0 0
Adjustments to Income 0 0 0 0
Inc. for Primary EPS -59 -37 -59 -37
Pri/Bas EPS Ex. XOrd -0.003 -0.002 -0.003 -0.002
Disc Opns + Xord Items 0 0 0 0
Pri/Bas EPS In. XOrd -0.003 -0.002 -0.003 -0.002
Primary/Basic Avg Sh 20,877.72 20,993.86 20,877.72 20,993.86
Dilutd EPS Excl XOrd -0.003 -0.002 -0.003 -0.002
Dilutd EPS Incl XOrd -0.003 -0.002 -0.003 -0.002
Common Dividends/Shr 0.000 0.000 0.000 0.000
Sanguine Corporation SELECTED BALANCE SHEET Page 9 of 10
(Thousands of U.S. Dollars)
YEAR ENDING QUARTER ENDING
12/31/96 12/31/97 03/31/97 03/31/98
Cash & ST Investments 1 0 1 0
Receivables 0 0 0 0
Total Current Assets 1 0 1 0
LT Investments 0 0 0 0
Fixed Assets 2 1 2 1
Total Assets 13 1 13 1
Accounts Payable 25 36 50 28
ST Debt & Curr LTD 70 104 79 114
Total Current Liab. 354 500 413 527
LT Debt & Cap Leases 0 0 0 0
Total Liabilities 354 500 413 527
Preferred Stock 0 0 0 0
Common/Paid In Capital 618 627 618 635
Retained Earnings -959 -1,125 -1,018 -1,162
Total Equity -341 -498 -400 -527
Shares Outstanding 20,878 20,978 20,878 21,010
Sanguine Corporation SELECTED STMT OF CASH FLOWS Page 10 of 10
INDIRECT METHOD (Thousands of U.S. Dollars)
ANNUAL YEAR TO DATE
12M 12/31/96 12M 12/31/97 3M 03/31/97 3M 03/31/98
Net Income -210 -166 -59 -37
Depreciation & Amort. 1 1 0 0
Non Cash Items 82 19 0 0
Total Operating CF -28 -35 -10 -11
Capital Expenditures 0 0 0 0
Total Investing CF 0 0 0 0
Dividends Paid 0 0 0 0
Sale (Purch.) of Stock 3 0 0 0
Net Borrowings 26 34 10 11
Total Financing CF 29 34 10 11
Exchange Rate Effect 0 0 0 0
Net Change In Cash 0 0 0 0
Oper CF-Cap Exp-Div Pd -28 -35 -10 -11
|
